These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Photosensitizers in prostate cancer therapy. Gheewala T; Skwor T; Munirathinam G Oncotarget; 2017 May; 8(18):30524-30538. PubMed ID: 28430624 [TBL] [Abstract][Full Text] [Related]
49. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. Xiao Z; Owen RJ; Liu W; Tulip J; Brown K; Woo T; Moore RB Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):106-14. PubMed ID: 20510305 [TBL] [Abstract][Full Text] [Related]
50. Comparative characterization of the cellular uptake and photodynamic efficiency of Foscan® and Fospeg in a human prostate cancer cell line. Petri A; Yova D; Alexandratou E; Kyriazi M; Rallis M Photodiagnosis Photodyn Ther; 2012 Dec; 9(4):344-54. PubMed ID: 23200016 [TBL] [Abstract][Full Text] [Related]
51. Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas. Betz CS; Rauschning W; Stranadko EP; Riabov MV; Albrecht V; Nifantiev NE; Hopper C Lasers Surg Med; 2008 Jul; 40(5):300-11. PubMed ID: 18563776 [TBL] [Abstract][Full Text] [Related]
52. Photodynamic therapy in fibrosarcoma BALB/c animal model: Observation of the rebound effect. Eugenia EM; Ángel PM; Anabella G; Solange B; Carlos P; Horacio P; Mario G Photodiagnosis Photodyn Ther; 2018 Mar; 21():98-107. PubMed ID: 29155337 [TBL] [Abstract][Full Text] [Related]
53. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. Jankun J; Keck RW; Skrzypczak-Jankun E; Lilge L; Selman SH BJU Int; 2005 Jun; 95(9):1237-44. PubMed ID: 15892808 [TBL] [Abstract][Full Text] [Related]
54. Treatment of Kimura disease with photodynamic therapy: a case study. Abbas S; Jerjes W; Upile T; Vincent A; Hopper C Photodiagnosis Photodyn Ther; 2012 Mar; 9(1):83-6. PubMed ID: 22369733 [TBL] [Abstract][Full Text] [Related]
55. Biological responses of dog prostate and adjacent structures after meso-tetra-(m-hydroxyphenyl) chlorin and aluminum disulfonated phthalocyanine based photodynamic therapy. Chang SC; Chern IF; Hsu YH Proc Natl Sci Counc Repub China B; 1999 Oct; 23(4):158-66. PubMed ID: 10518316 [TBL] [Abstract][Full Text] [Related]
56. Liposomes in topical photodynamic therapy. Dragicevic-Curic N; Fahr A Expert Opin Drug Deliv; 2012 Aug; 9(8):1015-32. PubMed ID: 22731896 [TBL] [Abstract][Full Text] [Related]
57. Interstitial photodynamic therapy for a symptom-targeted treatment of complex vascular malformations in the head and neck region. Betz CS; Jäger HR; Brookes JA; Richards R; Leunig A; Hopper C Lasers Surg Med; 2007 Aug; 39(7):571-82. PubMed ID: 17868106 [TBL] [Abstract][Full Text] [Related]
58. Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study. Tan IB; Dolivet G; Ceruse P; Vander Poorten V; Roest G; Rauschning W Head Neck; 2010 Dec; 32(12):1597-604. PubMed ID: 20848401 [TBL] [Abstract][Full Text] [Related]
59. Tumor selectivity at short times following systemic administration of a liposomal temoporfin formulation in a murine tumor model. Svensson J; Johansson A; Gräfe S; Gitter B; Trebst T; Bendsoe N; Andersson-Engels S; Svanberg K Photochem Photobiol; 2007; 83(5):1211-9. PubMed ID: 17880517 [TBL] [Abstract][Full Text] [Related]
60. Photoinduced cytotoxicity and biodistribution of prostate cancer cell-targeted porphyrins. Sehgal I; Sibrian-Vazquez M; Vicente MG J Med Chem; 2008 Oct; 51(19):6014-20. PubMed ID: 18839477 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]